Effect of monoamine oxidase inhibitors on the disposition of intracisternally administered metaraminol-3H.
D000613:Aminobutyrates / Q000032:analysis / Q000378:metabolism; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001693:Biological Transport, Active; D001921:Brain / Q000378:metabolism; D001923:Brain Chemistry; D002247:Carbon Isotopes; D006834:Hydrazines / Q000494:pharmacology; D007490:Iproniazid / Q000494:pharmacology; D008297:Male; D008680:Metaraminol / Q000008:administration & dosage / Q000032:analysis / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009206:Myocardium / Q000378:metabolism; D009526:Nialamide / Q000494:pharmacology; D010293:Pargyline / Q000494:pharmacology; D010624:Phenelzine / Q000494:pharmacology; D051381:Rats; D014316:Tritium; D014508:Urea / Q000032:analysis / Q000378:metabolism
D000613:Aminobutyrates; D002247:Carbon Isotopes; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D014316:Tritium; D008680:Metaraminol; D014508:Urea; D010293:Pargyline; D000661:Amphetamine; D007490:Iproniazid; D010624:Phenelzine; D009526:Nialamide